**Supplementary Table 1. Univariate and Multivariate Analysis of Recurrence at 8 weeks**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Recurrence n=20** | **No Recurrence n=198** | **Univariate Analysis** | **Multivariate Analysis** |
| **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| **Patient Characteristics** |
| Age ≥ 65 years | 7 (35) | 106 (54) | 0.47 (0.18-1.22) | 0.114 |  |  |
| Diabetes | 9 (45) | 80 (40) | 1.21 (0.48-3.05) | 0.690 |  |  |
| Hemodialysis | 3 (15) | 14 (7) | 2.31 (0.61-8.88) | 0.195 |  |  |
| Immunocompromised | 8 (40) | 106 (54) | 0.58 (0.23-1.48) | 0.248 |  |  |
| **Disease characteristics** |
| Community-onset | 7 (35) | 69 (35) | 1.01 (0.38-2.64) | 0.989 |  |  |
| NAP1/B1/027 strain | 6 (30) | 16 (8) | 4.88 (1.65-14.42) | 0.008 | **4.69 (1.51-14.53)** | **0.007** |
| Fulminant | 8 (40) | 46 (23) | 2.20 (0.85-5.72) | 0.108 |  |  |
| Presence of circulatory shock | 7 (35) | 27 (14) | 3.41 (1.25-9.31) | 0.021 | **3.52 (1.22-10.11)** | **0.020** |
| **ABX characteristics** |
| Duration of systemic ABX, days, median (IQR) | 19 (9-29) | 21 (12-36) |  | 0.368 |  |  |
| *Any* use of high-risk ABX | 13 (65) | 131 (66) | 0.95 (0.36-2.49) | 0.917 |  |  |
| *Only* use of low-risk ABX | 2 (10) | 13 (7) | 1.58 (0.33-7.57) | 0.634 |  |  |
| **VAN characteristics** |
| Duration >14 days | 9 (45) | 69 (35) | 1.53 (0.61-3.87) | 0.367 |  |  |
| Aggregate duration of VAN, days, median (IQR)^ | 18 (15-21) | 21 (15-30) |  | 0.377 |  |  |
| VAN discontinued prior to ABX | 4 (20) | 11 (6) | 4.25 (1.21-14.88) | 0.037 | **4.81 (1.28-18.08)** | **0.020** |

OR: odds ration; CI: confidence interval; ABX: systemic antibiotics; VAN: oral vancomycin

All values are reported as n (%) unless otherwise specified

^Aggregate duration included combined days of TX, PPX, and taper